Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Biogen
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:focus |
gene therapy
inherited retinal diseases |
| gptkbp:founded |
2013
|
| gptkbp:founder |
gptkb:Robert_MacLaren
|
| gptkbp:headquarters_location |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nightstar Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:NSR-REP1
gptkb:NSR-RPGR |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:NITE
|
| gptkbp:target |
X-linked retinitis pigmentosa
choroideremia |
| gptkbp:website |
https://www.nightstartx.com/
|
| gptkbp:bfsParent |
gptkb:Biogen
|
| gptkbp:bfsLayer |
5
|